Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
暂无分享,去创建一个
L. Dogliotti | E. Bollito | R. Scarpa | M. Tucci | A. Berruti | A. Mosca | C. Terrone | A. Angeli | C. Cracco | R. Tarabuzzi | M. Torta | L. Russo
[1] A. Sciarra. Neuroendocrine differentiation in prostate adenocarcinoma. , 2007, European urology.
[2] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[3] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[4] P. Kantoff,et al. Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] David C. Smith,et al. Combined modality treatment for prostate cancer: role of chemotherapy. , 2003, Seminars in Oncology.
[6] S. Monti,et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma , 2003, The Prostate.
[7] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Kevin Regan,et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Bostwick,et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. , 2002, The Journal of urology.
[10] T. H. van der Kwast,et al. Different profiles of neuroendocrine cell differentiation evolve in the PC‐310 human prostate cancer model during long‐term androgen deprivation , 2002, The Prostate.
[11] K. Akakura,et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. , 2002, The Journal of urology.
[12] D. Bostwick,et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin , 2001, The Prostate.
[13] S. Fosså,et al. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer , 2001, The Prostate.
[14] P. di Sant'Agnese,et al. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] H. Bonkhoff. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] S. Cappia,et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] L. Dogliotti,et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] J. Hugosson,et al. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. , 2000, Urology.
[19] R. Montironi,et al. Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.
[20] L. Dogliotti,et al. Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.
[21] P. Abrahamsson. Neuroendocrine cells in tumour growth of the prostate. , 1999, Endocrine-related cancer.
[22] J. Holaday,et al. Antiangiogenic activity of prostate-specific antigen. , 1999, Journal of the National Cancer Institute.
[23] T. H. van der Kwast,et al. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. , 1999, The American journal of pathology.
[24] H. Bonkhoff. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status , 1998, The Prostate. Supplement.
[25] P. di Sant'Agnese,et al. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma , 1998, The Prostate. Supplement.
[26] H. Frierson,et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.
[27] L. McWilliam,et al. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. , 1997, British journal of urology.
[28] R. De Angelis,et al. Estimating Relative Survival of Italian Cancer Patients from Sparse Cancer Registries Data , 1997, Tumori.
[29] A. Partin,et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.
[30] P. di Sant'Agnese,et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.
[31] H. Moch,et al. Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.
[32] T. H. van der Kwast,et al. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.